CE Holdings (4320) FY2026 Q1 Earnings Report

Quick View

Executive Summary

FY2025 Q1 results show revenue of 5.06 billion yen (YoY +33.2%), operating income of 655 million yen (YoY +68.0%), ordinary income of 670 million yen (YoY +68.4%), and net income of 420 million yen (YoY +81.0%). The Healthcare Solution segment drove top-line expansion with sales reaching 4.94 billion yen, representing 97.6% of total revenue. Operating margin improved to 13.0% from 10.3% in the prior year period. However, equity declined to 8.31 billion yen from 8.84 billion yen, while total assets decreased to 12.35 billion yen from 12.75 billion yen, reflecting balance sheet contraction despite strong earnings performance.

Performance Drivers

Revenue growth of 33.2% was primarily driven by the Healthcare Solution segment, which expanded 34.3% YoY to 4.94 billion yen. The segment accounted for 97.6% of total sales, positioning it as the core business. Marketing Solution segment contributed 120 million yen, remaining relatively flat YoY at 120 million yen versus 120 million yen. Operating income rose 68.0% to 655 million yen, outpacing revenue growth due to improved operating leverage. Segment operating income for Healthcare Solution increased 70.2% to 661 million yen with margin expansion to 13.4% from 10.6%, while Marketing Solution segment operating income declined slightly to 1.4 million yen from 1.5 million yen. Cost of sales grew 35.4% to 3.92 billion yen, moderately above revenue growth, reflecting some procurement pressure. Selling, general and administrative expenses increased 23.1% to 485 million yen, demonstrating effective cost discipline with SG&A ratio declining to 9.6% from 10.4%. Non-recurring factors include impairment losses of 15.2 million yen recorded in the prior year period related to Micron Corporation within the Healthcare Solution segment, which did not recur in the current quarter. The gap between ordinary income and net income widened to 250 million yen from 170 million yen, primarily due to higher income tax expenses increasing from 1.55 billion yen to 2.51 billion yen, resulting in an effective tax rate of 37.2% versus 40.2% in the prior period. This represents a revenue up, profit up pattern with accelerating margin expansion.

Segment Analysis

Healthcare Solution segment generated revenue of 4.94 billion yen and operating income of 661 million yen, establishing it as the core business with 97.6% revenue share. Segment operating margin reached 13.4%, expanding 2.8 percentage points from 10.6% in the prior year period. Marketing Solution segment recorded revenue of 120 million yen with operating income of 1.4 million yen, yielding a margin of 1.2%. The significant margin differential of 12.2 percentage points between segments reflects the Healthcare Solution business model's superior profitability profile. Healthcare Solution's operating income contribution increased 70.2% YoY, substantially exceeding its 34.3% revenue growth rate, indicating strong operational leverage as the segment scales. Marketing Solution maintained stable revenue but experienced marginal profit decline, suggesting potential pricing pressure or cost inflation in this smaller segment.

Key Metrics

[Profitability] Operating margin of 13.0% improved 2.7 percentage points from 10.3% in the prior year period. Net profit margin reached 8.3%, expanding from 6.1% YoY. ROE stood at 4.5%, calculated as net profit margin 7.4% multiplied by total asset turnover 0.41 and financial leverage 1.49. The relatively modest ROE reflects the company's conservative capital structure despite strong profitability improvements. [Cash Quality] Cash and deposits totaled 5.27 billion yen, representing 42.7% of total assets. Working capital management shows concerns with accounts receivable at 2.73 billion yen indicating DSO of approximately 197 days, substantially elevated for typical business operations. Work-in-process inventory reached 302 million yen, comprising 96.9% of total inventory, suggesting project-based business characteristics with extended production cycles. [Investment Efficiency] Total asset turnover of 0.41 reflects the asset-intensive nature of operations. Investment securities increased 76.0% to 718 million yen from 408 million yen, representing deployment of excess cash into marketable securities. [Financial Health] Equity ratio of 67.3% remains robust despite declining from 69.3% in the prior period. Current ratio of 274.3% indicates strong short-term liquidity. Interest-bearing debt totaled 778 million yen with debt-to-equity ratio of 0.09, reflecting minimal leverage. Debt-to-capital ratio of 8.6% confirms conservative financial positioning.

Cash Flow Analysis

Cash and deposits increased 12.9% YoY to 5.27 billion yen, benefiting from strong profit generation despite balance sheet contraction. Working capital movements show accounts receivable expanding 35.3% to 2.73 billion yen, outpacing revenue growth and indicating extended collection cycles. Accounts payable increased 36.3% to 1.60 billion yen from 1.33 billion yen, suggesting effective supplier credit utilization to partially offset receivables buildup. Work-in-process inventory grew 50.0% to 302 million yen, reflecting project pipeline expansion but also tying up operating capital. Investment securities position increased by 310 million yen, representing cash deployment into financial assets for yield enhancement. Short-term liquidity coverage remains adequate with cash-to-current-liabilities ratio of 1.70, providing substantial cushion for operational needs. The elevated receivables balance relative to revenue growth warrants monitoring as it may indicate customer payment delays or contract structures with deferred billing terms.

Earnings Quality

Ordinary income of 670 million yen versus operating income of 655 million yen shows net non-operating contribution of approximately 15 million yen. Non-operating income totaled 41 million yen while non-operating expenses amounted to 26 million yen, resulting in modest net financial income. The prior year period showed non-recurring impairment losses of 15.2 million yen in the Healthcare Solution segment related to Micron Corporation, which did not repeat in the current quarter, improving earnings quality. Non-operating income represents 0.8% of revenue, consisting primarily of interest and dividend income along with miscellaneous financial gains. The effective tax rate of 37.2% reduced pretax income of 670 million yen to net income of 420 million yen, with tax burden coefficient of 0.564 indicating significant tax drag on earnings. The absence of operating cash flow disclosure limits assessment of cash-backed earnings quality, though the strong cash position and profit growth suggest underlying earnings generation. The 197-day DSO metric raises concerns about revenue recognition quality and collection efficiency, potentially indicating aggressive revenue booking or customer credit issues. Overall earnings quality appears mixed, with strong operating performance offset by working capital management concerns.

Guidance Update

Full-year guidance projects revenue of 15.00 billion yen (YoY -5.3%), operating income of 1.50 billion yen (YoY +6.3%), and net income of 870 million yen. Q1 progress rates are: revenue 33.7% (13.7 percentage points ahead of standard 25% pace), operating income 43.7% (18.7 percentage points ahead), and net income 48.3% (23.3 percentage points ahead). The significantly front-loaded performance suggests either strong seasonal weighting in Q1 or potential guidance conservatism. The full-year revenue decline forecast of -5.3% contrasts sharply with Q1's 33.2% growth, implying expected substantial deceleration or potential one-time factors in Q1 results. Operating income guidance of 1.50 billion yen represents only 6.3% growth despite strong Q1 momentum, suggesting management anticipates margin pressure or revenue normalization in subsequent quarters. The substantial outperformance versus quarterly run-rate expectations warrants close monitoring of Q2-Q4 trajectory to assess guidance achievability and potential revision catalysts.

Shareholder Returns

Annual dividend is projected at 0 yen per share for the current fiscal year according to full-year forecast data, indicating no dividend payment planned. This represents a change from the prior period's dividend policy. The absence of dividend despite profitable operations suggests management prioritizes capital retention for growth investments or balance sheet flexibility. No share buyback activities were disclosed for the quarter. The zero dividend policy despite positive earnings may reflect cash flow considerations, particularly given the elevated accounts receivable position and working capital requirements for business expansion. Total return ratio stands at 0% as neither dividends nor buybacks are currently implemented.

Risk Factors

Customer concentration and extended payment terms expose the company to collection risk, evidenced by DSO of 197 days representing 6.5 months of sales outstanding. A default or payment delay from major customers could materially impact cash flow despite strong reported earnings. The Healthcare Solution segment represents 97.6% of revenue, creating significant business concentration risk whereby adverse developments in healthcare market demand, regulatory changes, or competitive dynamics would directly impact overall corporate performance with limited diversification buffer. High work-in-process inventory at 96.9% of total inventory reflects project-based business model risks, including potential project delays, scope changes, or customer acceptance issues that could impair inventory valuation or extend cash conversion cycles beyond current elevated levels.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis) The company's operating margin of 13.0% and revenue growth of 33.2% position it as a growth-oriented player in the healthcare solutions sector. Historical trend analysis shows operating margin improvement from prior periods, reaching 13.0% in 2026 with net profit margin of 8.3%. The 33.2% YoY revenue expansion substantially exceeds typical industry growth rates, suggesting market share gains or exposure to high-growth subsegments. However, the company's ROE of 4.5% appears modest relative to profitability metrics, reflecting conservative capital structure with equity ratio of 67.3%. The project-based business model evidenced by high work-in-process inventory and extended DSO represents operational characteristics common in healthcare IT and solutions providers. Industry participants typically face similar working capital intensity with project milestone-based revenue recognition. The company's zero dividend policy diverges from mature industry players who typically maintain stable payouts, suggesting growth-stage capital allocation priorities. Comparison context: Healthcare Solutions sector, Reference period: FY2025 Q1 vs. historical trends, Source: Proprietary analysis of publicly available earnings data.

Key Takeaways from Earnings

Strong profit growth momentum with operating income expanding 68.0% and net income up 81.0% demonstrates operational leverage as the Healthcare Solution segment scales, though sustainability depends on addressing working capital concerns and validating full-year guidance trajectory given Q1's front-loaded performance. Balance sheet strength with 67.3% equity ratio and minimal leverage provides financial flexibility, yet the absence of shareholder returns via dividends or buybacks despite profitability and 5.27 billion yen cash position suggests management prioritizes internal investment or maintains caution regarding cash flow sustainability given elevated receivables. The contrast between strong Q1 results (43.7% operating income progress) and modest full-year growth guidance (+6.3% operating income) creates uncertainty regarding business linearity, potential one-time factors in Q1, or management conservatism that warrants monitoring through subsequent quarterly results to assess earnings quality and guidance credibility.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q1 was a strong start, with revenue growth, operating leverage, and earnings expansion materially ahead of the company’s full-year run-rate. Revenue increased 33.2% YoY to ¥5.06bn. Operating income rose 68.0% YoY to ¥655m, more than twice the rate of revenue growth. Ordinary income increased 68.4% YoY to ¥667m. Profit attributable to owners of parent grew 87.3% YoY to ¥376m, or ¥22.60 per share. Gross margin improved to 22.6% from 24.1% in the prior-year quarter, a compression of roughly 150bp. Despite the gross-margin decline, operating margin expanded to 13.0% from 10.3%, an improvement of approximately 270bp. The margin expansion was driven by SG&A declining 6.7% YoY to ¥488m while revenue expanded sharply. Healthcare Solutions was the principal earnings engine, accounting for virtually all segment profit. Its segment margin improved from 10.6% to 13.4%. The Marketing Solutions business remained small and low margin, with revenue broadly flat and segment profit declining modestly. Non-operating income included a ¥11m gain on sales of investment securities, but its scale was limited at about 0.2% of revenue. The effective tax rate calculated from income tax expense and profit before tax was 37.2%, while the owner-level tax burden was 0.564 because profit attributable to non-controlling interests also reduces earnings attributable to owners. The supplied annualized ROE was excellent at 18.1%, supported primarily by profitability and asset turnover rather than aggressive leverage. Liquidity remained very strong, with cash of ¥5.27bn and a current ratio of 274.3%. Q1 revenue reached 33.7% of the full-year forecast and operating income reached 43.7%, both well ahead of a standard 25% first-quarter progress rate. The company’s full-year outlook nevertheless embeds a 5.3% revenue decline and only 6.3% operating-income growth, implying a substantially more conservative earnings profile for the remaining quarters.

Profitability Analysis

The supplied annualized DuPont ROE of 18.1% decomposes into a 7.4% net profit margin, 1.638x annualized asset turnover, and 1.49x financial leverage. Profitability and operating leverage are the primary drivers of returns, while financial leverage is moderate. Consolidated operating margin rose 270bp YoY to 13.0%, placing it in the upper end of the stated 8-15% good range. The main positive operating-leverage signal was SG&A expense declining 6.7% YoY despite 33.2% revenue growth. Gross margin declined about 150bp YoY to 22.6%, indicating that the operating-margin improvement came from fixed-cost absorption and SG&A discipline rather than improved gross profitability. Healthcare Solutions revenue grew 34.3% YoY to ¥4.94bn and segment profit increased 70.2% YoY to ¥661m. Healthcare Solutions was the core business, contributing approximately 99.8% of total segment profit, and its segment margin expanded 280bp to 13.4%. Marketing Solutions revenue was essentially unchanged at ¥120m, while segment profit declined 5.5% YoY to ¥14m; its 1.2% segment margin remains substantially below the healthcare business. The ¥11m investment-securities gain contributed modestly to ordinary income, so the majority of the earnings acceleration was operational. The gap between ordinary income of ¥667m and profit attributable to owners of ¥376m reflects income taxes of ¥248m and ¥43m attributable to non-controlling interests. The tax-burden quality alert is relevant because the owner-level tax burden is only 0.564, below the 0.60 benchmark. However, the tax expense calculated against profit before tax is 37.2%, rather than above 40%; the lower owner-level burden is also affected by non-controlling interests. Sustaining the current operating margin depends on Healthcare Solutions maintaining project execution and on SG&A remaining disciplined as revenue normalizes.

Growth Assessment

Growth was concentrated in Healthcare Solutions, where Q1 revenue expanded ¥1.26bn YoY. This segment accounted for 97.6% of consolidated revenue and therefore determines consolidated growth sustainability. The segment’s profit growth exceeded sales growth, demonstrating favorable operating leverage in the quarter. Marketing Solutions generated ¥120m of revenue, broadly unchanged YoY, and does not currently provide a meaningful secondary growth driver. Q1 revenue progress was 33.7% of the ¥15.0bn full-year forecast, 8.7 percentage points above the standard 25% first-quarter pace. Operating-income progress was 43.7% of the ¥1.50bn forecast, 18.7 percentage points above the standard pace. Ordinary-income progress was 44.5% of forecast and profit attributable to owners reached 43.2% of the ¥870m forecast. The Q1 operating margin of 13.0% also exceeds the approximately 10.0% margin embedded in the full-year operating-income forecast. This leaves room for full-year achievement if business trends remain stable, but it also implies that management expects lower revenue and/or margin in later quarters. The full-year forecast calls for revenue to decline 5.3% YoY while operating income rises 6.3% YoY, making sustained cost efficiency and mix critical. The absence of a material impairment charge in the current quarter is favorable versus the ¥15m impairment recorded in the prior-year quarter within Healthcare Solutions.

Financial Health

Financial health is robust. Current assets of ¥8.49bn exceeded current liabilities of ¥3.10bn by ¥5.40bn, producing working capital of ¥5.40bn. The current ratio was 274.3% and the quick ratio was 274.2%, providing a substantial liquidity buffer. Cash and deposits of ¥5.27bn alone exceeded current liabilities by approximately ¥2.17bn. Accounts receivable were ¥2.73bn, while inventories excluding work in process were minimal at ¥5m. Total equity was ¥8.31bn, equivalent to 67.3% of total assets, and liabilities represented 32.7% of assets. The reported debt-to-equity ratio was 0.49x, well below the 2.0x warning threshold. Debt-to-capital was 8.6%, consistent with a conservative capital structure. Interest coverage was exceptionally strong at 273.14x, as operating income of ¥655m greatly exceeded ¥2m of interest expense. Long-term loans were ¥778m, with a ¥571m current portion of long-term loans, but the company’s cash balance provides ample coverage for near-term maturities. Investment securities increased ¥310m YoY, or 76.0%, to ¥718m; this increase raises the balance-sheet exposure to market-value movements and investment-realization gains, although the position remains only 5.8% of total assets. Trade accounts payable increased ¥425m YoY, or 36.3%, to ¥1.60bn, broadly accompanying the increase in operating scale and supporting working capital. Goodwill was only ¥7m, equal to 0.1% of equity and assets, so balance-sheet dependence on acquisition value retention is negligible. Intangible assets were ¥983m, or 8.0% of assets, remaining below the 20% concentration benchmark.

Notable B/S Changes

Investment securities: +¥3.10bn (+76.0%) to ¥7.18bn - increased exposure to market-value fluctuations and securities disposal gains; the balance equals 5.8% of total assets. Accounts payable: +¥4.25bn (+36.3%) to ¥15.97bn - growth in supplier obligations accompanied the higher operating scale and contributed to working-capital support. Cash and deposits: +¥5.34bn (+11.3%) to ¥52.67bn - strengthens liquidity and provides substantial coverage for current liabilities and scheduled loan repayments. Accounts receivable: -¥8.27bn (-23.2%) to ¥27.34bn - receivables declined despite revenue growth, supporting balance-sheet efficiency.

Cash Flow Quality

Work in process was ¥302m, representing 96.9% of total inventory including work in process. This directly addresses the HIGH_WIP_RATIO alert: the root cause is a project-oriented asset mix in which unfinished work dominates inventory rather than completed goods. This can be typical in software, healthcare-system implementation, and development work, where revenue recognition and billing milestones can differ from production progress. The impact is that project delays, cost overruns, or customer acceptance issues could defer conversion of work in process into revenue and cash. The current work-in-process balance declined 6.8% YoY from ¥324m, which is constructive, although its concentration remains high. Contract liabilities increased 32.3% YoY to ¥100m, providing a limited level of customer prepayments against project execution.

Dividend Sustainability

The full-year dividend forecast is ¥24.00 per share. Against forecast EPS of ¥52.28, the implied dividend payout ratio is approximately 45.9%. This is below the 60% sustainability benchmark and leaves a meaningful portion of earnings available for reinvestment, debt service, and balance-sheet resilience. The forecast dividend is also covered by Q1 profit attributable to owners of ¥22.60 per share on a cumulative basis, although quarterly earnings should not be interpreted as a quarterly dividend commitment. The cash position of ¥5.27bn and conservative debt-to-capital ratio of 8.6% provide additional financial capacity for the stated dividend. Dividend sustainability is principally tied to delivery of the ¥870m full-year profit attributable to owners forecast and the maintenance of Healthcare Solutions profitability.

Risk Assessment

Business risks include Healthcare Solutions accounted for 97.6% of revenue and approximately 99.8% of segment profit, creating substantial concentration in healthcare IT project demand, customer budgets, and implementation execution., Work in process of ¥302m represents 96.9% of total inventory including WIP. Delayed implementation, cost overruns, or customer acceptance delays could pressure margins and defer conversion into revenue., Marketing Solutions generated only ¥14m of segment profit on ¥120m of revenue, with a 1.2% segment margin. Its limited scale and weak profitability constrain diversification benefits., Healthcare IT faces industry-specific risks from cybersecurity incidents, personal-data protection requirements, interoperability standards, and changes in medical-provider IT spending..

Financial risks include The owner-level tax burden of 0.564 is below the 0.60 benchmark. Its root cause is the combination of ¥248m of tax expense and ¥43m of profit attributable to non-controlling interests relative to ¥667m of profit before tax. The calculated statutory effective tax rate is 37.2%, so the quality alert does not indicate an effective tax rate above 40%, but it does reduce owner-level earnings conversion., Investment securities rose 76.0% YoY to ¥718m. This creates greater exposure to valuation volatility and to the non-recurring nature of gains such as the ¥11m Q1 gain on sales of investment securities., The full-year forecast assumes revenue declines 5.3% YoY despite Q1 revenue growth of 33.2% YoY, indicating that later-quarter demand and/or project timing may be less favorable than the first-quarter trend..

Key concerns include The largest risk to the investment case is whether the 270bp operating-margin expansion can persist once Q1 fixed-cost absorption and favorable project mix normalize., Gross margin declined about 150bp YoY even as operating margin improved, making continued SG&A discipline essential to preserving profitability., The Q1 operating-income progress rate of 43.7% is 18.7 percentage points above the standard first-quarter pace, creating sensitivity to any later-quarter slowdown relative to the conservative full-year forecast..

Investment Implications

Key takeaways include Revenue grew 33.2% YoY and operating income grew 68.0% YoY, reflecting strong operating leverage., Operating margin improved to 13.0%, while Healthcare Solutions segment margin reached 13.4%., The supplied annualized ROE of 18.1% is above the 15% excellent benchmark and is supported by profitability and asset turnover rather than high leverage., Liquidity is strong, with a 274.3% current ratio, ¥5.27bn of cash, and debt-to-capital of 8.6%., Full-year forecast progress is ahead of the standard Q1 pace, but the forecast itself assumes weaker revenue conditions later in the year..

Metrics to watch include Healthcare Solutions revenue growth and segment margin, Consolidated gross margin relative to SG&A expense growth, Work-in-process balance, project acceptance, and conversion into revenue, Progress toward the ¥15.0bn revenue and ¥1.50bn operating-income forecasts, Investment-securities movements and recurring versus disposal-related non-operating income, Owner-level tax burden and profit attributable to non-controlling interests.

Regarding relative positioning, The company combines above-benchmark annualized ROE, a good-range operating margin, substantial net liquidity, and very low goodwill exposure. Its relative strength is the high-margin Healthcare Solutions franchise, while its relative limitation is the small, low-margin Marketing Solutions segment and concentration of earnings in project-oriented healthcare IT.